Overview
I completed my hematology/oncology fellowship training and Masters of Science in Translational Research at the University of Pennsylvania. I am dedicated to the treatment of lymphoma and have developed a specific interest in the T cell lymphomas. I am inspired by the opportunity for the development of new treatments, and aspire to be a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy. My recent research has focused on the development of immune therapies for the treatment of T cell malignancies. I believe that novel approaches are needed in this group of diseases.
Current Appointments & Affiliations
Assistant Professor of Medicine
·
2021 - Present
Medicine, Hematological Malignancies,
Medicine
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
A Cautionary Tale: Florid Splenic γδ T-cell Proliferation and False-Positive T-cell Clonality by PCR Leads to a Grave Misdiagnosis.
Journal Article Clin Lymphoma Myeloma Leuk · October 2021 The discrimination of benign from malignant lymphoproliferative disorders is sometimes difficult because there can be overlap in their histological and immunophenotypic features. In such situations, molecularly based clonality testing is often used to disc ... Full text Link to item CiteComplete Response of a Young Woman With MYD88WT Bing-Neel Syndrome on Ibrutinib Monotherapy Following a Single Cycle of B Hyper-CVAD/IT MTX.
Journal Article Clin Lymphoma Myeloma Leuk · November 2020 Full text Link to item CiteRecent Grants
Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms
Clinical TrialPrincipal Investigator · Awarded by University of Michigan · 2024 - 2029Regeneron: III:REGN1979: A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 × ANTI-CD3BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (D
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2029HCRN-LYM21-544
Clinical TrialPrincipal Investigator · Awarded by Hoosier Cancer Research Network, Inc · 2024 - 2027View All Grants
Education, Training & Certifications
The University of Chicago, Pritzker School of Medicine ·
2010
M.D.